Sang et al. showed that the inhibition of either phosphoinositide 3-kinase (PI3K) or AKT serine-threonine protein kinase reduced the proliferation of EBV+ B-cell lines from PTLD patients synergistically with the use of RAPA [125]. The gene discussed is AKT1; the disease is post-transplant lymphoproliferative disease.